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Griffithsin (GRFT), Cyanovirin-N (CV-N) and Scytovirin (SVN) are lectins that inhibit HIV-1 infection by
binding to multiple mannose-rich glycans on the HIV-1 envelope glycoproteins (Env). Here we show that
these lectins neutralize subtype C primary virus isolates in addition to Env-pseudotyped viruses obtained
from plasma and cervical vaginal lavages. Among 15 subtype C pseudoviruses, the median IC50 values were
0.4, 1.8 and 20.1 nM for GRFT, CV-N and SVN, respectively, similar to what was found for subtype B and A.
Analysis of Env sequences suggested that concomitant lack of glycans at positions 234 and 295 resulted in
natural resistance to these compounds, which was confirmed by site-directed mutagenesis. Furthermore, the
binding sites for these lectins overlapped that of the 2G12 monoclonal antibody epitope, which is generally
absent on subtype C Env. This data support further research on these lectins as potential microbicides in the
context of HIV-1 subtype C infection.
© 2010 Elsevier Inc. All rights reserved.
Introduction
Griffithsin (GRFT) is a lectin isolated from the red algae Griffithsia
sp. found in the coastal waters off New Zealand (Mori et al., 2005). It is
a 121 amino acid dimeric protein with a domain-swapped structure
(Ziolkowska et al., 2006). This lectin neutralizes HIV-1 by binding to
mannose-rich glycans found on the envelope glycoproteins. Both
native and recombinant GRFT display potent antiviral activities
against laboratory-adapted strains and primary isolates of M- and T-
tropic HIV-1. This compound was also shown to be active against a
broad range of HIV-1 including 4 subtype C viruses (O'Keefe et al.,
2009). A second lectin, Cyanovirin-N (CV-N) isolated much earlier
from the blue green algae Nostoc ellipsosporum (Boyd et al., 1997) is a
101 amino acid protein that has been shown to exist either as a quasi-
symmetric two-domain monomer or as a domain-swapped dimer
(Barrientos et al., 2002; Botos and Wlodawer, 2005). Like GRFT, CV-N
binds tomannose-rich glycans and both native and recombinant CV-N
have shown potent anti-HIV-1 activity in vitro (Bolmstedt et al., 2001;
Esser et al., 1999). A third protein, Scytovirin (SVN) is a 95 amino acid
lectin isolated from the cyanobacterium Scytonema varium (Bokesch
et al., 2003). SVN is expressed as a single amino acid chain with
extensive internal sequence duplication. This protein is found
exclusively as a monomer and has been shown to neutralize both
laboratory-adapted strains and primary isolates of HIV-1 by interact-
ing with mannose-rich glycans on the viral envelope (Moulaei et al.,
2007; Xiong et al., 2006; Ziolkowska and Wlodawer, 2006).
As a result of their ability to block HIV-1 entry in vitro, GRFT, CV-N
and SVN have been proposed as potential microbicides to prevent the
sexual transmission of HIV-1. Although these compounds are not HIV-
specific, they target high-mannose arrays that are present on all HIV
envelope glycoproteins. Since such arrays are uncommon in mam-
malian cells, these compounds are not likely to be toxic to human cells
in vivo even at relatively high concentrations (Balzarini, 2005;
Balzarini and Van Damme, 2007). Furthermore, a recombinant GRFT
produced in the tobacco-like plant Nicotiana benthamiana was shown
to be non-toxic in a rabbit vaginal irritancy model and in human
cervical explants (O'Keefe et al., 2009). Although GRFT, CV-N and SVN
have not yet been tested in human clinical trials it is noteworthy that
CV-Nwas shown to be effective in protecting pigtailedmacaques after
vaginal and rectal challenges with high dose of SHIV 86.9P (Tsai et al.,
2004, 2003).
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HIV-1 can develop resistance to CV-N by partial deglycosylation,
specifically deleting glycans at positions 230, 289, 295, 332, 339, 386,
392 and 448 in HIV-IIIB (Balzarini et al., 2006; Hu et al., 2007). This
suggests that resistance to CV-N may be hard to generate as it will
require multiple mutations in the viral genome although additional
studies using primary viruses are needed. Some of these glycans also
form part of the epitope for the broadly neutralizing monoclonal
antibody (mAb) 2G12. This antibody directly binds glycans at
positions 332, 339 and 392 (Calarese et al., 2003), while glycans
at positions 295, 386 and 448 though not directly involved in this
epitope, may influence its conformation (Sanders et al., 2002; Scanlan
et al., 2002). Subtype C viruses are commonly resistant to 2G12
neutralization. This has been attributed to their frequent lack of the
295 glycosylation site although re-introduction of this glycan only
partially restores sensitivity to this mAb (Binley et al., 2004; Chen
et al., 2005; Gray et al., 2007b). Although it is known that GRFT and
SVN bind to mannose-rich glycans found on HIV-1 envelope, the
specific glycans involved in this binding have not yet been identified.
Despite subtype C viruses being responsible for over 50% of global
infections (http://www.unaids.org) many of the antiviral studies
with GRFT, CV-N and SVN have been done on subtype B viruses.
Significant differences exist in the pattern of glycosylation between
subtype B and C envelope glycoproteins (Zhang et al., 2004). For
example, about 80% of subtype B envelopes are glycosylated at
position 295 while only ∼20% of subtype C viruses are glycosylated at
the same position. The opposite pattern is observed at position 230
where over 70% of subtype C envelopes are glycosylated compared to
only 20% of subtype B. It is known that differences between subtypes
can affect their susceptibility to neutralizing agents as for the 2G12
mAb described above (Binley et al., 2004; Gray et al., 2006). Therefore,
we aimed to examine the sensitivity of a large collection of subtype C
viruses to GRFT, CV-N and SVN and compare these to subtypes B and A
strains. Furthermore, we examined the role of the 2G12 epitope in
these lectin's binding sites.
Results
GRFT, CV-N and SVN neutralize HIV-1 subtype C isolates from blood and
cervico-vaginal lavages
To determine the ability of GRFT, CV-N and SVN to inhibit HIV-1
subtype C infection of peripheral bloodmononuclear cells (PBMC), we
performed neutralization assays using blood-derived subtype C pri-
mary isolates Du151, COT9 and Du179. Viral infection was measured
by p24 ELISA after 4 days of culture. The concentration of lectin that
inhibited 80% of virus infection (IC80) is reported. All three lectins
neutralized these viruses in a dose-dependent manner (Fig. 1). The
IC80 values were similar for all viruses with GRFT and CV-N being
more potent than SVN. The mean IC80 values for all 3 viruses were
42.7±4.4, 77.0±18.2 and 368.4±22.7 nM for GRFT, CV-N and SVN,
respectively.
Next we tested the ability of GRFT, CV-N and SVN to inhibit 50%
(IC50) HIV-1 infection in the TZM-bl cell-line based neutralization
assay (Montefiori, 2004). For this we used 11 subtype C Env-pseu-
dotyped viruses cloned from plasma of adult patients with acute or
early HIV infection and from pediatric patients during chronic
infection (see Materials and methods for details). For comparison
we included 6 viruses from the subtype B panel described by Li et al.
(Li et al., 2005) and 5 subtype A viruses from acutely infected
individuals (Long et al., 2002; Neilson et al., 1999). All viruses used the
CCR5 coreceptor. GRFT and CV-N potently neutralized most subtype C
viruses with a median IC50 of 0.4 and 1.2 nM, respectively, (Fig. 2)
which were not significantly different. SVN was the least effective
with a median IC50 of 20.1 nM. The single-cycle pseudovirus assay
required considerably lower concentrations of lectin to inhibit viral
infection compared to the PBMC assay even when comparing IC80
values (not shown). Nevertheless, the trends were the same in both
assays as was noted for Du151.2 and COT9.6 pseudoviruses compared
to their matched primary viruses in PBMC (Table 1 and Fig. 1). There
were no significant differences in mean IC50 values between subtypes
C, B and A viruses for all 3 lectins (pN0.05) (Table 1). However, 2
subtype C viruses (CAP206.08J and CAP63.A9J) and one subtype B
virus (CAAN5342.A2) showed unusually high IC50 values suggesting
natural resistance to these compounds (Fig. 2). We also found a
significant positive correlation (pb0.05) between GRFT and CV-N
sensitivity for subtype C, and between CV-N and SVN for both subtype
C and B Env-pseudotyped viruses (data not shown).
We also tested the sensitivity of four subtype C Env isolated from
cervical–vaginal lavages (CVL) of HIV-1 positive women during acute
infection (Bronwen Lambson, unpublished data). These viruses also
showed varying sensitivities to the lectins with one (CAP177.cvl96)
showing a high level of resistance to both GRFT and CV-N (Fig. 3). For
CAP63.cvl6GA a matched blood sample was also available and the CVL
and plasma derived viruses showed similar sensitivities to the three
lectins (Table 1). In general, viruses from CVL were inhibited by GRFT,
CV-N and SVN with IC50 in the nanomolar range similar to those
derived from plasma.
Correlation between HIV-1 mannose-rich glycosylation patterns and
sensitivity to GRFT, CV-N and SVN
Given that these lectins bind mannose-rich glycans, we analyzed
the predicted glycosylation patterns of all the viruses used in our
neutralization assays to determine if there was any correlation with
their sensitivity to GRFT, CV-N and SVN. This analysis included all 11
predicted mannose-rich sites on HIV-1 gp120 some of which are
involved in mAb 2G12 binding (labeled with asterisks in Table 1).
Significant differences were noted between subtypes as previously
reported (Zhang et al., 2004). In this study, 13 of the 15 subtype C
viruses lacked the 295 glycan compared to more than half of the
subtype B and A viruses where this glycan was intact. On average,
viruses from subtypes C and B lacked 2 of the 11 predicted glycans
although there was a range with some viruses lacking as many as 5
sites. The subtype A viruses had a larger number of missing sites and
they all lacked the 230 and 289 glycans. Only one virus was predicted
to have all 11 glycans, a subtype C virus (CAP270.cvl44) isolated from
CVL.
The five viruses (four subtype C, including two from CVL, and one
subtype B) that were the least sensitive to GRFT lacked both the 234
and 295 glycosylation sites. Two of these five viruses (CAP206.08J and
CAAN5342.A2) were also the least sensitive to CV-N and SVN and a
third (CAP177.cvl96) also required above average levels of CV-N for
inhibition. We concluded that the absence of both the 234 and 295
glycosylation sites was responsible for this decreased sensitivity to
these lectins. However, the lack of either of these two glycans in
isolation did not affect sensitivity. Thus WITO4160.33 and Q842.d12
which lacked the 234 glycan but had the 295 glycan showed similar
sensitivity to viruses with both glycans. Similarly viruses that lacked
the 295 glycan but retained the glycan at position 234 (most subtype
C viruses) were not unusually resistant. Overall there was no cor-
relation between the number of missing glycans and resistance to
these lectins. The fewer mannose-rich glycosylation sites on subtype
A Envs did not reduce their sensitivity.
The 234 and 295 glycosylation sites are involved in GRFT, CV-N and SVN
neutralization of HIV-1
In order to examine the contribution of the glycan at position 295
to lectin neutralization, we introduced this glycosylation site in 3
viruses, Du151.2, COT9.6 and COT6.15, that already had the 234 glycan
(see Table 1). For all three viruses the introduction of the 295
glycosylation site further increased their sensitivity to GRFT by 7 to 50
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fold (Table 2). However, the addition of the 295 glycan had no effect
on their sensitivity to CV-N and SVN suggesting that this glycan is
essential for GRFT binding only. As GRFT is more promiscuous in its
binding to high-mannose oligosaccharides than either SVN or CV-N
(which only bind to oligomannose-8 or -9) this could also indicate
that the glycan at position 295 is a smaller oligosaccharide such as
oligomannose-5 or -7.
We also introduced both the 234 and 295 glycosylation sites into 3
viruses, CAP206.08J, CAP63.A9J and CAAN5342.A2 that lacked both of
these sites and were the most resistant to the lectins, to determine if
this would increase their sensitivity. Reconstruction of the 234
glycosylation site in both CAP206.08J and CAP63.A9J reduced virus
infectivity of TZM-bl cells by ∼2-fold. We were unable to determine
whether this was due to a decrease in the production of viral particles
in 293T cells or a defect in the virus's capacity to infect cells. However,
the introduction of 295 and to a lesser extent 234, increased the
sensitivity of all three viruses to GRFT (Fig. 4A). Furthermore, when
these two glycans were introduced simultaneously there was an
additional increase in sensitivity. The introduction of the 234 and 295
glycosylation sites also had a similar effect on CV-N sensitivity, with
the exception of CAP63.A9J where addition of the 234 glycosylation
site had no effect (Fig. 4B). For SVN, the 234 glycosylation site had a
more significant impact on sensitivity than the 295 although for
CAP63.A9J addition of a glycan at position 295 actually increased
Fig. 1. GRFT, CV-N, and SVN inhibit HIV-1 subtype C infection of PBMC. Three primary isolates, Du151 (A), COT9 (B) and Du179 (C) were treated with increasing concentrations of
GRFT, CV-N and SVN before infection of PBMC. Data are shown as the average plus standard deviations of three independent experiments. Untreated virus is shown in black (positive
control). The IC80 values of the lectins are indicated next to each graph.
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sensitivity above the wild-type (Fig. 4C). Collectively, these data
suggested that the 234 and 295 glycosylation sites are involved in
lectin binding to the HIV-1 envelope glycoproteins and subsequent
virus neutralization, although for CV-N and SVN their involvement
may be strain-dependent.
GRFT, CV-N and SVN binding sites overlap the 2G12 epitope
Since five of the 11 mannose-rich sites on gp120 form the 2G12
mAb epitope, we investigated whether lectin binding interfered with
access to this epitope. We used a competition ELISA to measure the
amount of p24 antigen captured onto 2G12-coated plates after pre-
incubation of the virus with GRFT, CV-N or SVN. The 2G12 mAb was
competed against itself as a positive control. We tested the subtype B
virus QH0692.42 which is sensitive to 2G12 with an IC50 of 2.8 μg/ml
(Li et al., 2005). Subtype C viruses are generally insensitive to 2G12
and so we used modified subtype C gp160 where the 2G12 epi-
tope had been partially reconstituted (Gray et al., 2007b). Thus,
for COT6.15 the addition of glycans at positions 295 and 448
(COT6-V295N/S448N) increased sensitivity from IC50 N100 μg/ml
to 64.5 μg/ml. There was also increased binding of the 2G12 mAb
to this mutant (Gray et al., 2007b). For COT9.6 the addition of
glycans at positions 295 and 442 (COT9-V295N/K442N) increased
the sensitivity to 2G12 from an IC50 of 68.7 μg/ml to 33.9 μg/ml.
Pre-incubation of the 3 viruses with each lectin significantly
reduced the amount of virus captured onto 2G12-coated plates
suggesting competition between these compounds (Fig. 5). Similar to
what was seen in the neutralization assays; GRFT and CV-N were
more potent than SVN at inhibiting virus capture. The effect was dose-
dependent although higher amounts of lectin were required to inhibit
virus capture compared to neutralization. However, for all 3 viruses,
virus capture by 2G12 was inhibited at equivalent lectin concentra-
tions despite the 10–20 fold difference in sensitivities to 2G12
neutralization. Together with the mutagenesis results (Table 2) these
data suggested an overlap between the 2G12 epitope and GRFT, CV-N
and SVN binding sites.
Discussion
In this studywe have shown that HIV-1 subtype C viruses, including
those from the vaginal tract are sensitive to the mannose-binding
lectins, GRFT, CV-N and SVN. Despite subtype-specific differences in
mannosylation patterns, their sensitivity was similar to what has been
previously reported for subtype B viruses (Bokesch et al., 2003; Boyd et
al., 1997;Mori et al., 2005). GRFT and CV-Nweremore potent than SVN
which required higher concentrations to prevent HIV-1 entry. We
identified glycans at positions 234 and 295, in addition to the 2G12mAb
epitope, as playing an important role in the binding of these lectins. Our
data support the continued development of GRFT, CV-N and SVN as
potential microbicides since these compounds are likely to be effective
against HIV-1 subtype C mucosal transmissions.
Inhibition of HIV-1 subtype C infection by GRFT, CV-N and SVN in
both primary cells and a cell line were similar although higher
concentrations were required for PBMC neutralization. The increased
sensitivity in TZM-bl cells compared to PBMC is consistent with
studies of antibody neutralization, where single-cycle pseudovirus
assays are generally more sensitive than PBMC infectivity assays
(Fenyo et al., 2009). The longer duration of culture and multiple
replication cycles in the PBMC assay probably account for this. Unlike
Huskens et al., we did not find any enhanced infectivity of HIV-1 in
PBMC treated with CV-N, indicating that CV-N was not mitogenic in
our hands (Huskens et al., 2008). The greater neutralization potency
of GRFT and CV-N compared to SVNmay be due to the fact that a GRFT
dimer has six mannose-binding sites and a CV-N dimer has four
binding sites. In contrast, the SVN monomer has only two mannose
residue binding sites (Moulaei et al., 2007; Ziolkowska et al., 2006;
Ziolkowska and Wlodawer, 2006). The correlation between IC50
values of the compounds within certain subtypes suggested that these
lectins share some binding sites, a finding which we confirmed for a
few loci. Although, we have shown efficacy of these compounds
against subtype C viruses in primary PBMC, it will be important to test
the anti-HIV activity of GRFT, CV-N and SVN using dendritic cells and
macrophages as these cells play an important role during the sexual
transmission of HIV (Lederman et al., 2006; Pohlmann et al., 2001).
Subtype C viruses isolated from both adult and pediatric HIV
infections as well as those from acute and chronic infection were
sensitive to these lectins. Our data are in line with previously reported
Fig. 2. GRFT, CV-N, and SVN inhibit HIV-1 infection in the TZM-bl assay. Neutralization
of HIV-1 subtype C, B and A pseudoviruses by GRFT (A), CV-N (B), and SVN (C). HIV-1
subtype B and A pseudoviruses were used for comparison to subtype C. Each virus was
tested at least three times. Pseudoviruses are ranked by GRFT sensitivity.
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inhibitory concentrations for subtype B viruses and confirm that these
compounds are active against multiple subtypes (Bokesch et al., 2003;
Boyd et al., 1997;Mori et al., 2005; O'Keefe et al., 2009). Given that CV-
N and GRFT are being proposed as microbicides, we also considered it
important to test them against viruses found in the vaginal tract. It has
been reported that virus compartmentalization can occur during HIV
infection raising the possibility of differential sensitivity of viruses
from CVL compared to blood (Kemal et al., 2003). However, our data
showed that CAP63.A9J from plasma and CAP63.cvl6GA from CVL of
the same HIV-positive woman had similar sensitivity to all three
lectins. We attributed this to the fact that these two viruses have
minimal genetic differences and the samemannose-rich glycosylation
patterns (Table 1). Also these viruses are from early infection and,
therefore, it may be too early for compartmentalization to develop.
Nevertheless, further studies with more pairs of plasma and CVL
viruses, from the same individual with a demonstrated virus com-
partmentalization, are needed to determine if viruses from CVL are as
sensitive as those present in blood.
Despite differences in mannose-rich glycosylation patterns, sub-
type C, B and A viruses (Zhang et al., 2004) showed similar sen-
sitivities to GRFT, CV-N, and SVN. This result was unexpected given
that these compounds bind high-mannose residues. Analysis of the
glycosylation patterns suggested that absence of glycans at positions
234 and 295 was associated with natural resistance to GRFT and in
some cases to CV-N and SVN. Since subtype C viruses generally lack
295N it was surprising that these viruses were as sensitive to the
lectins as subtype B and A viruses that generally retained this site.
However, a concomitant lack of the 234 glycosylation site was also
required to reduce sensitivity and since this glycan is present on ∼80%
of subtype C viruses, this may account for the comparable sensitivity
with subtype B. The important role of these glycans in conferring
sensitivity to these lectins was confirmed by site-directed mutagen-
esis. Interestingly, when the 295 or 234 glycosylation sites were
individually reconstituted they had a significant impact in some
viruses. This suggests that in natural Env there may be considerable
redundancy or overlap in the glycans that are bound by these
compounds. We did not find a correlation between the number of
predicted mannose-rich glycans and sensitivity to the lectins, unlike
an earlier study on CV-N in subtype B viruses (Balzarini et al., 2006).
For example, CAP270.cvl44 which had all predicted 11 mannose-rich
glycans was less sensitive to GRFT than viruses that had fewer
predicted glycans. In fact our data suggested that the location of the
glycan was more important than the number of glycans. Thus, in
addition to mannose-rich glycans there may be other factors in the
viral envelope that determine the sensitivity to GRFT, CV-N and SVN.
These factors may include the Env structure, that can result in glycans
that occupy the same position being exposed differently, and the fact
that not all potential sites are glycosylated (Go et al., 2009).
Three studies examining CV-N escape pathways using laboratory-
adapted HIV-1 subtype B viruses selected in vitro showed that
deletion of glycans caused resistance to CV-N (Balzarini et al., 2006;
Hu et al., 2007; Witvrouw et al., 2005). The large number of glycans
involved suggested that these compounds have a high genetic barrier
to resistance. In this study, we showed that for subtype C primary
Table 1
Pattern of predicted mannose-rich glycans on gp120 of HIV-1 and sensitivity to GRFT, CV-N, and SVN.
HIV-1 envelope
pseudoviruses
Predicted N-linked mannose-rich glycosylation sitesa IC50 (nM)b
230 234 241 262 289 295c 332c 339c 386c 392c 448c GRFT CV-N SVN
Subtype C (n=15)
CAP177.cvl96 x x x x x 55.9±5.0 7.5±1.1 21.8±5.4
CAP206.08J x x x x x 30.9±6.2 18.0±1.2 112.8±1.1
CAP63.A9J x x 23.2±6.5 1.8±0.3 29.8±13.3
CAP63.cvl6GA x x 25.7±2.6 3.1±0.1 43.8±8.5
CAP261.cvl93 x x 4.2±0.4 1.8±0.6 6.2±0.9
Du151.2 x x x 1.5±0.8 2.0±1.0 27.5±9.6
COT9.6 x 1.2±0.2 3.9±2.7 57.6±26.9
COT6.15 x x 0.4±0.2 0.9±0.5 10.8±6.9
CAP228.51J x x 0.4±0.1 3.1±0.9 20.1±11.1
CAP270.cvl44 0.3±0.1 0.8±0.07 11.7±4.8
RP6.6 x x 0.2±0.1 1.1±0.1 11.3±3.3
TM7.9 x x 0.2±0.1 1.1±0.4 12.1±1.6
CAP45.G3J x x x x 0.2±0.1 0.4±0.1 16.9±8.8
CAP210.E8J x 0.2±0.0 1.2±0.2 33.1±1.1
CAP256.F7J x x 0.1±0.0 1.1±0.1 6.7±2.3
Median 0.4 1.8 20.1
Subtype B (n=6)
CAAN5342.A x x x 11.7±2.3 16.7±6.0 187.6±38.6
THRO4156.18 x x 1.2±0.3 3.0±0.8 42.6±6.9
AC10.0.29 x x x 0.9±0.2 0.3±0.1 24.5±12.9
QHO692.42 x x 0.2±0.1 2.5±0.8 27.3±14.1
PVO.4 x x 0.1±0.0 1.0±0.1 25.2±14.0
WITO4160.33 x x 0.05±0.0 1.5±0.5 24.8±10.1
Median 0.6 2.0 26.2
Subtype A (n=5)
Q168.a2 x x x x x 3.3±0.9 1.4±0.1 9.4±2.3
Q842.d12 x x x x 3.0±0.9 2.5±0.6 40.9±15.8
Q23.17 x x x 1.9±0.3 3.0±1.1 29.8±9.0
92RW009 x x x x 1.8±0.4 1.2±0.3 21.8±8.9
Q461.e2 x x x x x 0.12±0.06 1.2±0.3 18.9±4.2
Median 1.9 1.4 21.8
a Mannose-rich glycosylations were identified from the amino acid sequence of each envelope clone (Kwong et al., 1998; Leonard et al., 1990). Missingmannose-rich glycosylation
sites are marked by x. Viruses are ranked according to GRFT sensitivity.
b The IC50 is the concentration of GRFT, CV-N, and SVN that reduced HIV-1 infection by 50%. Mean±SD of 3 independent experiments is shown.
c Glycans involved in binding the monoclonal antibody 2G12.
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viruses that lack the 295 glycan, the absence of a single glycan at
position 234 could in some cases confer natural resistance to these
lectins. However, it is important to bear in mind that generating
resistant variants in vitro is likely to be different to identifying loci
associatedwith natural resistance as we have done here. Furthermore,
naturally-occurring resistant viruses may have compensatory muta-
tions that are isolate-specific or not commonly present. Indeed, glycan
234 may play an important functional role given its relative con-
servation in subtype C, and this is first study to report its involvement
in CV-N resistance in both subtypes C and B. Further studies are
needed to clearly elucidate the position and number of glycans
involved in CV-N resistance in primary viruses. It will also be
important to investigate the ability of HIV-1 to develop resistance to
GRFT and SVN, which may help to identify other GRFT and SVN
binding sites on the virus.
The ability of GRFT, CV-N and SVN to compete against the 2G12
MAb for binding to HIV-1 implicates the 2G12 epitope in the binding
of these compounds to HIV-1. These data are in agreement with
previous reports that glycans in the 2G12 epitope are involved in CV-
N and GRFT binding to HIV-1 gp120 (Esser et al., 1999; Mori et al.,
2005). However, our study is the first to demonstrate the involvement
of the 2G12 epitope in SVN binding to HIV-1. Nevertheless, the
involvement of this epitope in the activity of these lectins to subtype C
viruses is unclear as these viruses are generally insensitive to the
2G12 mAb (Chen et al., 2005; Gray et al., 2007b; Sanders et al., 2002).
The sensitivity of subtype C viruses to GRFT, CV-N and SVN is likely
due to the fact that these lectins bind many more sites than those
involved in the 2G12 epitope.
GRFT, CV-N and SVN are being actively pursued as microbicides
(Bokesch et al., 2003; O'Keefe et al., 2009; Shattock and Moore, 2003;
Xiong et al., 2006). The search for HIV microbicides is driven by the
challenges encountered indevelopingan effectiveHIVvaccine (Johnston
and Fauci, 2007) and the fact that the majority of HIV infections around
the world are sexually transmitted (Stein, 2003). Potential microbicides
include non-specific inhibitors such as buffering agents that inactivate
viruses bymaintaining the acidic pH in the vaginal tract andmoderately
specific inhibitors such as anionic polymers that neutralize the virus by
binding to its positively charged envelope glycoproteins (Cutler and
Justman, 2008). Anti-retroviral agents that target the reverse transcrip-
tase enzyme are being actively researched and herald a new phase in
prevention strategies. GRFT, CV-N and SVN, however, hold an advantage
over the above-mentioned compounds by selectively targeting the virus
to inhibit its entry into susceptible cells thereby preventing integration.
These compounds are small proteins that can be readily and cheaply
produced. Furthermore, commensal lactobacilli can be engineered to
produce these compounds which could be used to colonize vaginal
mucosa and create an environment hostile to HIV-1 (Pusch et al., 2005).
Since these compounds are not being developed as therapeutics, their
exclusive use as prevention agents would avert the complications that
may arise with the use of ARV as microbicides. In conclusion, our data
support the continued development of GRFT, CV-N and SVN as
microbicides against HIV-1 subtype C mucosal transmissions.
Materials and methods
Viruses, gp160 envelope (Env) clones, MAbs, cell lines and lectins
HIV-1 subtype C isolates Du151, and Du179 were isolated in South
Africa from individuals infected with HIV-1 subtype C (van Harmelen
Fig. 3. GRFT, CV-N, and SVN inhibit HIV-1 isolates from CVL. Sensitivity of 4 HIV-1
subtype C pseudoviruses containing functional envelope genes amplified from cervico-
vaginal lavages against GRFT (A), CV-N (B) and SVN (C) are shown.
Table 2
Effect of the 295 glycan on sensitivity to GRFT, CV-N and SVN.
Envelope GRFT CV-N SVN
IC50 (nM)a
Du151.2 Wild-type 1.5±0.8 2.0±1.0 27.5±9.6
V295N 0.03±0.02 1.2±0.4 32.5±4.9
COT9.6 Wild-type 1.2±0.2 3.9±2.7 57.6±26.9
V295N 0.06±0.04 4.4±3.9 63.0±35.9
COT6.15 Wild-type 0.4±0.2 0.9±0.5 10.8±6.8
V295N 0.06±0.0 1.1±0.6 16.1±9.2
Cases where the mutant IC50 was more than 5-fold lower than the wild-type virus IC50
are bolded.
a IC50 is the concentration of GRFT, CV-N, and SVN that reduces viral infection by 50%.
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et al., 2001). COT9 is a South African pediatric isolate (Choge et al.,
2006). HIV-1 subtype C Env clones Du151.2, CAP45.G3J, CAP210.E8J,
CAP206.08J, CAP63.A9J, CAP228.51J and CAP256.F7J were amplified
from South African individuals at the acute or early stage of HIV
infection (Gray et al., 2007a; Li et al., 2006). HIV-1 subtype B Env,
CAAN5342.A2, WITO4160.33, THRO4156.18, AC10.0.29, QH0692.42
and PVO.4 were amplified from acutely infected individuals from the
U.S.A, Trinidad and Tobago and Italy (Li et al., 2005). Subtype C Env
COT9.6, COT6.15, RP6.6 and TM7.9 were derived from South African
pediatric HIV-1 isolates. CAP63.cvl6GA, CAP177.cvl96, CAP261.cvl93
and CAP270.cvl44 were amplified from cervico-vaginal lavages (CVL)
obtained during the acute phase of infection from HIV-positive
women in the CAPRISA cohort in South Africa. The pSG3Δenv plasmid
was obtained from Beatrice Hahn. The mAb 2G12 was obtained from
the NIH Reference and Reagent Program and the IAVI Neutralizing
Antibody Consortium. The TZM-bl cell line was obtained from the NIH
Reference and Reagent Program (Cat No 8129) and the 293T cell line
was obtained from the American Type Culture Collection. Both cell
lines were cultured in DMEM containing 10% fetal bovine serum
(FBS). Cell monolayers were disrupted at confluence by treatment
with 0.25% trypsin in 1 mM EDTA. Recombinant GRFT, CV-N, and SVN
purified from E. coli were provided by Dr. Barry O'Keefe from NCI.
HIV-1 neutralization assay in peripheral blood mononuclear cells
The neutralization assay in PBMC was carried out as described by
Bures et al. (Bures et al., 2000). Briefly, a three-fold dilution series of
GRFT, CV-N, and SVN in 40 μL of RPMI 1640 containing 20% FBS and
interleukin-2 (growth medium) was prepared in triplicate in a U-
bottom 96-well plate. Five hundred TCID50 of HIV-1 primary isolate in
15 μL of growth medium was added to each well and the plate was
incubated at 37 °C for 1 h. Then 100 μL of 5×106 cells/mL phytohe-
magglutin/interleukin-2 stimulated PBMC (PHA-PBMCs) was added
to each well. The following day cells were washed 3 times with RPMI
1640 with 20% FBS and resuspended in 155 μL of fresh growth
medium. The culture supernatant was collected twice daily and
replaced with an equal amount of fresh growth medium. For each
harvest the p24 antigen concentration in the virus control wells was
measured by ELISA using the Vironostika HIV-1 Antigen Microelisa
System (Biomerieux, Boseind, the Netherlands), according to the
manufacturer's instructions. The inhibitory activity of the lectins was
measured at the time-point that corresponded to the early part of the
linear growth period of the virus control (Zhou andMontefiori, 1997).
The IC80 were calculated by plotting the lectin concentration vs. the
percentage inhibition in a linear regression using GraphPad Prism 4.0.
Fig. 4. Glycans at positions 234 and 295 increase HIV-1 sensitivity to GRFT, CV-N and SVN. Glycosylation sites at 234 and/or 295 were introduced in CAP206.08J, CAP63.A9J and
CAAN5342.A2 by site-directedmutagenesis. Mutant viruses were tested in neutralization assays against GRFT (A), CV-N (B) and SVN (C) in TZM-bl cells. Each virus was tested at least
three times.
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Generation of Env-pseudotyped virus stock
HIV-1 pseudoviruses were generated by co-transfection of the Env
and pSG3Δenv plasmids (Wei et al., 2003) into 293T cells using the
Fugene transfection reagent (Roche Applied Science, Indianapolis, IN).
The TCID50 of each virus stock was quantified by infecting TZM-bl cells
with serial 5-fold dilutions of the supernatant in quadruplicate in the
presence of DEAE dextran (37.5 μg/mL) (Sigma-Aldrich, St. Louis,
MO). The Bright Glo™ Reagent (Promega, Madison, WI) was used to
measure infection after 48 h of tissue culture, according to the
manufacturer's instructions. Luminescence was measured in a Wallac
1420 Victor Multilabel Counter (Perkin-Elmer, Norwalk, CT). The
TCID50 was calculated as described elsewhere (Johnson and Byington,
1990).
Single-cycle neutralization assay (TZM-bl assay)
The pseudovirus neutralization assay was performed as described
elsewhere (Montefiori, 2004). Briefly, three-fold dilution series of
each lectin in 100 μL of DMEM with 10% FBS (growth medium) were
prepared in a 96-well plate in duplicate. Two hundred TCID50 of
pseudovirus in 50 μL of growth medium was added and the mixture
was incubated for 1 h at 37 °C. Then 100 μL of TZM-bl cells at a
concentration of 1×105 cells/mL containing 37.5 μg/mL of DEAE
dextran was added to each well and cultured at 37 °C for 48 h.
Infection was evaluated by measuring the activity of the firefly
luciferase. Titers were calculated as the inhibitory concentration that
causes 50% reduction (IC50) of relative light unit (RLU) compared to
the virus control (wells with no inhibitor) after the subtraction of the
background (wells without both the virus and the inhibitor).
HIV-1 virion capture assay
High binding 96-well plates (Corning Incorporated Corning, New
York, U.S.A) were coated overnight with 1 μg/well of themAb 2G12 in
NaHCO3 (pH 8.5). The coated plates were washed three times with
phosphate buffered saline (PBS) and blocked with 3% bovine serum
albumin (BSA) in PBS at 37 °C for 2 h. Pseudoviruses were pre-
incubated for an hour with different concentrations of 2G12, GRFT,
CV-N, or SVN. After discarding the blocking solution the virus was
added to the plate and left at 37 °C for 2 h. The plate was then washed
three times with PBS and captured viruses were lysed with 150 μL of
0.5% Triton X-100. The amount of p24 was measured using the
Vironostika HIV-1 Antigen Microelisa System (Biomerieux, Boseind,
The Netherlands), according to the manufacturer's instructions.
Site-directed mutagenesis
Putative glycosylation sites were introduced in HIV-1 gp120 using
the QuikChange Site-Directed Mutagenesis Kit (Stratagene, LaJolla,
CA). The presence of themutationwas confirmed by sequencing using
the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction
kit (Applied Biosystem, Foster City, CA) and resolved on the ABI 3100
automated genetic analyzer.
Statistical analysis
The Mann–Whitney t-test was used to compare the median IC50 of
each lectin for the neutralization of subtype C, B and A viruses and the
Wilcoxon matched pairs test was used to compare the median IC50 of
GRFT and CV-N for the neutralization of subtype C. GraphPad Prism
4.0 was used for the Spearman's nonparametric rank test. p-values
of≤0.05 were considered statistically significant.
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